Abstract

Glucocorticoids (GCs) are broadly prescribed for numerous pathological conditions due to their anti-inflammatory, antiallergic and immunosuppressive effects, among other actions. Nevertheless, GCs can produce undesired diabetogenic side effects through interactions with the regulation of glucose homeostasis. Under conditions of excess and/or long-term treatment, GCs can induce peripheral insulin resistance (IR) by impairing insulin signalling, which results in reduced glucose disposal and augmented endogenous glucose production. Additionally, GCs can promote abdominal obesity, elevate plasma fatty acids and triglycerides and suppress osteocalcin synthesis in bone tissue. In response to GC-induced peripheral IR and in an attempt to maintain normoglycaemia, pancreatic beta-cells undergo several morphofunctional adaptations that result in hyperinsulinaemia. Failure of beta-cells to compensate for this situation favours glucose homeostasis disruption, which can result in hyperglycaemia, particularly in susceptible individuals. GC treatment does not only alter pancreatic beta-cell function; pancreatic alpha-cells are also affected by GC actions that can lead to hyperglucagonaemia, further contributing to glucose homeostasis imbalance and hyperglycaemia. Additionally, the release of other islet hormones, such as somatostatin and amylin, are also affected by GC administration. These undesired GC actions merit further consideration for the design of improved GC therapies without diabetogenic effects. In summary, in this review, we consider the impact of GC treatment on peripheral IR, islet function and glucose homeostasis.